Keio multicenter trial in high-dose interferon-α2b treatment for chronic hepatitis C

Hidetsugu Saito; Kanji Tsuchimoto; Shingo Miyaguchi; Shinichiro Tada; Kentaro Sawaguchi; Kohichi Komatsu; Kohtaro Kaneko; Tetsu Watanabe; Toshio Morizane; Hiromasa Ishii

doi:10.2302/kjm.45.161

Keio multicenter trial in high-dose interferon-α2b treatment for chronic hepatitis C

Hidetsugu Saito, Kanji Tsuchimoto, Shingo Miyaguchi, Shinichiro Tada, Kentaro Sawaguchi, Kohichi Komatsu, Kohtaro Kaneko, Tetsu Watanabe, Toshio Morizane, Hiromasa Ishii

School of Pharmacy

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

Abstract

The efficacy of two different high-dose treatment of IFN-α2b was evaluated in this study. Serum hepatitis C virus (HCV) RNA levels were semi-quantified by simplified reverse transcription polymerase chain reaction. Seventy-one patients with chronic hepatitis C received 10 million units of IFN-α2b daily for 2 weeks or thrice a week for 24 weeks. Alanine aminotransferase (ALT) levels overall normalized in 78.1% and 51.6% of the cases at the end of the therapy and 6 months after that, respectively. HCV RNA disappeared in 71.9% and 35.7% of the patients at the end of the therapy and 6 months after that, respectively. There was no significant difference between the 2 different regimes. The efficacy of the treatment was fair in cases in which the pretreatment level of the viral amount was low. The results of this study indicate that daily administration of IFN in the first 2 weeks during a 6-month course does not increase the efficacy of the therapy in such a high-dose treatment regime.

Original language	English
Pages (from-to)	161-167
Number of pages	7
Journal	Keio Journal of Medicine
Volume	45
Issue number	3
DOIs	https://doi.org/10.2302/kjm.45.161
Publication status	Published - 1996 Sept

Keywords

chronic hepatitis C
dose study
interferon
prediction

ASJC Scopus subject areas

Medicine(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2302/kjm.45.161

Cite this

@article{0b207bc562424e9f80614b5f20599177,

title = "Keio multicenter trial in high-dose interferon-α2b treatment for chronic hepatitis C",

abstract = "The efficacy of two different high-dose treatment of IFN-α2b was evaluated in this study. Serum hepatitis C virus (HCV) RNA levels were semi-quantified by simplified reverse transcription polymerase chain reaction. Seventy-one patients with chronic hepatitis C received 10 million units of IFN-α2b daily for 2 weeks or thrice a week for 24 weeks. Alanine aminotransferase (ALT) levels overall normalized in 78.1% and 51.6% of the cases at the end of the therapy and 6 months after that, respectively. HCV RNA disappeared in 71.9% and 35.7% of the patients at the end of the therapy and 6 months after that, respectively. There was no significant difference between the 2 different regimes. The efficacy of the treatment was fair in cases in which the pretreatment level of the viral amount was low. The results of this study indicate that daily administration of IFN in the first 2 weeks during a 6-month course does not increase the efficacy of the therapy in such a high-dose treatment regime.",

keywords = "chronic hepatitis C, dose study, interferon, prediction",

author = "Hidetsugu Saito and Kanji Tsuchimoto and Shingo Miyaguchi and Shinichiro Tada and Kentaro Sawaguchi and Kohichi Komatsu and Kohtaro Kaneko and Tetsu Watanabe and Toshio Morizane and Hiromasa Ishii",

year = "1996",

month = sep,

doi = "10.2302/kjm.45.161",

language = "English",

volume = "45",

pages = "161--167",

journal = "Keio Journal of Medicine",

issn = "0022-9717",

publisher = "Keio University School of Medicine",

number = "3",

}

TY - JOUR

T1 - Keio multicenter trial in high-dose interferon-α2b treatment for chronic hepatitis C

AU - Saito, Hidetsugu

AU - Tsuchimoto, Kanji

AU - Miyaguchi, Shingo

AU - Tada, Shinichiro

AU - Sawaguchi, Kentaro

AU - Komatsu, Kohichi

AU - Kaneko, Kohtaro

AU - Watanabe, Tetsu

AU - Morizane, Toshio

AU - Ishii, Hiromasa

PY - 1996/9

Y1 - 1996/9

N2 - The efficacy of two different high-dose treatment of IFN-α2b was evaluated in this study. Serum hepatitis C virus (HCV) RNA levels were semi-quantified by simplified reverse transcription polymerase chain reaction. Seventy-one patients with chronic hepatitis C received 10 million units of IFN-α2b daily for 2 weeks or thrice a week for 24 weeks. Alanine aminotransferase (ALT) levels overall normalized in 78.1% and 51.6% of the cases at the end of the therapy and 6 months after that, respectively. HCV RNA disappeared in 71.9% and 35.7% of the patients at the end of the therapy and 6 months after that, respectively. There was no significant difference between the 2 different regimes. The efficacy of the treatment was fair in cases in which the pretreatment level of the viral amount was low. The results of this study indicate that daily administration of IFN in the first 2 weeks during a 6-month course does not increase the efficacy of the therapy in such a high-dose treatment regime.

AB - The efficacy of two different high-dose treatment of IFN-α2b was evaluated in this study. Serum hepatitis C virus (HCV) RNA levels were semi-quantified by simplified reverse transcription polymerase chain reaction. Seventy-one patients with chronic hepatitis C received 10 million units of IFN-α2b daily for 2 weeks or thrice a week for 24 weeks. Alanine aminotransferase (ALT) levels overall normalized in 78.1% and 51.6% of the cases at the end of the therapy and 6 months after that, respectively. HCV RNA disappeared in 71.9% and 35.7% of the patients at the end of the therapy and 6 months after that, respectively. There was no significant difference between the 2 different regimes. The efficacy of the treatment was fair in cases in which the pretreatment level of the viral amount was low. The results of this study indicate that daily administration of IFN in the first 2 weeks during a 6-month course does not increase the efficacy of the therapy in such a high-dose treatment regime.

KW - chronic hepatitis C

KW - dose study

KW - interferon

KW - prediction

UR - http://www.scopus.com/inward/record.url?scp=0344532668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344532668&partnerID=8YFLogxK

U2 - 10.2302/kjm.45.161

DO - 10.2302/kjm.45.161

M3 - Article

C2 - 8897759

AN - SCOPUS:0344532668

SN - 0022-9717

VL - 45

SP - 161

EP - 167

JO - Keio Journal of Medicine

JF - Keio Journal of Medicine

IS - 3

ER -

Keio multicenter trial in high-dose interferon-α2b treatment for chronic hepatitis C

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this